Please login to the form below

Not currently logged in
Email:
Password:

Biogen

This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck stops verubecestat study

Another Alzheimer's bust as Merck stops verubecestat study

Another Alzheimer's bust as Merck stops verubecestat study. Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai. ... Merck &Co has abandoned the phase III trial of its BACE1 inhibitor verubecestat in Alzheimer’s in

Latest news

  • Biogen cuts $217m deal for Karyopharm neurology drug Biogen cuts $217m deal for Karyopharm neurology drug

    Biogen cuts $217m deal for Karyopharm neurology drug. The biotech hopes to begin phase I trials of KPT-350 by the end of the year. ... Biogen has agreed a deal to license a brain disease candidate from Karyopharm for $10m upfront, and up to $217m in

  • Biogen cuts $217n deal for Karyopharm neurology drug Biogen cuts $217n deal for Karyopharm neurology drug

    Biogen cuts $217n deal for Karyopharm neurology drug. The biotech hopes to enter KPT-350 in a phase 1 study by the end of the year. ... Biogen has agreed a deal to license a brain disease candidate from Karyopharm for $10m upfront, and up to $217m in

  • NICE finally starts review of Biogen’s Spinraza for SMA NICE finally starts review of Biogen’s Spinraza for SMA

    NICE finally starts review of Biogen’ s Spinraza for SMA. Will evaluate the treatment based on its Single Technology Appraisal process. ... The National Institute for Health and Care Excellence (NICE) has started its appraisal of Biogen’s Spinraza

  • Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

    French pharma firm offers $105 apiece for the spin-out’s shares. After missing out on earlier bids for Medivation and Actelion, Sanofi has agreed to buy Biogen haematology spin-out ... Bioverativ separated from Biogen last year to create a stand-alone

  • Pfizer drops neuroscience R&D, cutting 300 jobs Pfizer drops neuroscience R&D, cutting 300 jobs

    enzyme. Pfizer’s decision comes after its former head of neuroscience R&D Michael Ehlers left to take up the top R&D role at Biogen in 2016.

More from news
Approximately 90 fully matching, plus 257 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen was the largest seller in the CNS market in 2017 and this is forecast to continue, ”says Rahael Maladwala, analyst, neurology and ophthalmology, GlobalData. ... Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales

  • Simplifying HCP access to digital information Simplifying HCP access to digital information

    Biogen, one of Align Biopharma’s founding members. ... Other founding members include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis and Pfizer.

  • Deal Watch May 2017

    Two pre phase 2 molecules to treat neuro-degenerative disease have been licensed to Biogen and Roche for a combined $1.085bn. ... BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for  progressive supranuclear palsy.

  • Managing medication non-adherence Managing medication non-adherence

    efficacious. Biogen has been playing in this space for a few years now and conducted a clinical trial with PatientsLikeMe that showed how people living with multiple sclerosis (MS) can use

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri

More from intelligence
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 14 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics